Acceleron shares not pricing in PAH opportunity, says Piper Sandler » 05:0505/2605/26/20
While Acceleron Pharma…
While Acceleron Pharma shares are up 85% year-to-date even before the PULSAR data have been detailed, sotatercept's opportunity in pulmonary arterial hypertension is not fully baked into the stock, Piper Sandler analyst Christopher Raymond tells investors in a research note after taking over coverage of the name. While management has "provided a decent floor in terms of expectations for the data, we like the chances for upside," says the analyst. He keeps an Overweight rating on the shares with a $135 price target.
|Over a week ago|
Acceleron management to meet virtually with Oppenheimer » 08:1305/1405/14/20
Virtual Meeting with…
Virtual Meeting with management to be held on May 14 hosted by Oppenheimer.
Acceleron announces pulication of sotatercept data in STM journal » 16:0405/1305/13/20
Acceleron Pharma announced that research published in the journal Science Translational Medicine describes how a murine version of the investigational agent sotatercept acts to restore balance in key signaling pathways whose disruption drives the disease pathology of pulmonary arterial hypertension. The research may provide a mechanistic rationale for the positive topline results reported earlier this year from the PULSAR Phase 2 clinical trial of sotatercept in patients with PAH. The article reports that in experimental human cell-based tissue and animal models of pulmonary hypertension and PAH, sotatercept exhibited consistent effects across multiple components of disease, including suppressed proliferation of pulmonary arterial smooth muscle and microvascular endothelial cells, reduced pulmonary pressures, lessened right ventricular hypertrophy, improved right ventricular function, and attenuated vascular remodeling. The anti-remodeling effects were not seen with a PAH standard-of-care therapy included in the study as a comparator. The researchers concluded that sotatercept exerted its beneficial effects on these pathologic hallmarks by selectively binding the TGF-beta superfamily ligands activin A, activin B, and growth differentiation factor (GDF) 8 and GDF11. Signaling of these ligands, which may induce cellular proliferation, has been found to be upregulated in PAH-which in turn may impair signaling of bone morphogenetic protein receptor type 2 (BMPR-II), which is thought to be protective.
Acceleron price target raised to $127 from $104 at SVB Leerink » 09:2005/1205/12/20
SVB Leerink analyst…
SVB Leerink analyst Geoffrey Porges raised the firm's price target on Acceleron to $127 from $104 and keeps an Outperform rating on the shares. The analyst notes that Acceleron reported Q1 earnings and provided interim corporate updates following the first full quarter of Reblozyl sales and reported encouraging Q1 net Reblozyl sales of about $8M and royalties of $1.5M. Considering that this revenue was all attributed to the less significant beta thalassemia indication, and expectations were negligible, this is a creditable revenue result, he contends.
Acceleron reports Q1 EPS (95c), consensus (86c) » 16:0805/1105/11/20
Reports Q1 revenue…
Reports Q1 revenue $4.34M, consensus $5.26M. "Acceleron is off to a strong start in 2020, propelled by one of the most eventful time periods in the Company's history," said Habib Dable, President and Chief Executive Officer of Acceleron. "The breadth and depth of our hematology program has been on full display, owing to the publication of the MEDALIST and BELIEVE Phase 3 luspatercept trial results in the prestigious New England Journal of Medicine and the recent FDA approval of REBLOZYL for the treatment of anemia in a population of patients with lower-risk MDS. We're thrilled that this first-in-class erythroid maturation agent, having received approvals in two distinct indications over a span of just five months, is now available in the U.S. to patients who have long needed a new option for treating their chronic anemias."
Acceleron price target raised to $123 from $99 at Credit Suisse » 06:5005/0805/08/20
Credit Suisse analyst…
Credit Suisse analyst Martin Auster raised the firm's price target on Acceleron to $123 from $99 and keeps an Outperform rating on the shares, saying that from the PULSAR top-line, he knows that sotatercept delivered statistical significant on a variety of meaningful endpoints, including PVR, 6mw, and WHO Functional Class changes. Auster is confident of that sotatercept can deliver deliver at least on the opportunity framed by the non-oral PAH market of $1B-$1.5B annual sales.
Acceleron participates in a virtual bus tour with Piper Sandler » 07:2505/0705/07/20
Biotech Analyst Brill…
Acceleron participates in a virtual bus tour with Piper Sandler » 04:5505/0705/07/20
Biotech Analyst Brill…
Acceleron receives PRIME designation for sotatercept from EMA » 07:0805/0405/04/20
Acceleron announced that…
Acceleron announced that the European Medicines Agency, or EMA, has granted Priority Medicines, or PRIME, designation to sotatercept for the treatment of patients with pulmonary arterial hypertension, or PAH. "Receiving PRIME designation for sotatercept from the EMA mere weeks after the FDA granted it Breakthrough Therapy designation further strengthens our belief that sotatercept could eventually alter the treatment landscape in PAH dramatically," said Habib Dable, President and CEO of Acceleron. "We're delighted that in their initial assessments of our clinical trial data, regulatory authorities in the US and Europe have put forth a path that could potentially help us expedite delivery of sotatercept to patients in need of new therapeutic options."
Acceleron participates in a virtual bus tour with Piper Sandler » 14:3705/0305/03/20
Biotech Analyst Brill…